KBY Biotech Indexv0.0.34
Search
← Pipeline|Zenoglumide

Zenoglumide

Phase 2
000-8811
By Yuhan Corp
Source: Trial-derived·Trials: 1
Modality
Fusion Protein
MOA
RAS(ON)i
Target
USP1
Pathway
RNA Splicing
RCCLNAML
Development Pipeline
Preclinical
~Jun 2022
→ ~Sep 2023
Phase 1
~Dec 2023
→ ~Mar 2025
Phase 2
Jun 2025
→ Jan 2031
Phase 2Current
NCT07235669
1,779 pts·AML
2025-06→2031-01·Recruiting
1,779 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-01-044.8y awayPh2 Data· AML
Trial Timeline
Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031
P2
Recruit…
Catalysts
Ph2 Data
2031-01-04 · 4.8y away
AML
Recruiting|StartCompletionToday
Trials (1)
NCTPhaseIndicationStatusNEP
NCT07235669Phase 2AMLRecruiting1779ACR20
Competitors (10)
DrugCompanyPhaseTargetMOA
MRK-6781Merck & CoApprovedTIGITRAS(ON)i
ABB-2476AbbViePhase 1/2USP1FcRni
SNY-9073SanofiPhase 2B7-H3RAS(ON)i
TixarelsinVertex PharmaPhase 1ALKRAS(ON)i
FixatuximabLegend BiotechPreclinicalCFTRRAS(ON)i
ION-1378IonisNDA/BLATROP-2RAS(ON)i
180-3597Innovent BioPreclinicalSHP2RAS(ON)i
CGO-2579CG OncologyApprovedTIGITRAS(ON)i
TezesotorasibEnlivenPhase 2USP1MALT1i
ETN-506389bioPhase 1/2USP1Anti-Tau